Federated Hermes, Inc. Prelude Therapeutics Inc Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$4.61 - $8.5 $6,186 - $11,407	-1,342 Reduced 95.38%	65 $0
Q3 2022 Nov 14, 2022	BUY	$5.0 - $8.82 $5,705 - $10,063	1,141 Added 428.95%	1,407 $9,000
Q2 2022 Aug 15, 2022	BUY	$4.0 - $7.55 $1,064 - $2,008	266 New	266 $1,000
Q4 2021 Feb 14, 2022	SELL	$11.89 - $31.74 $4.85 Million - $13 Million	-408,100 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$25.78 - $38.65 $1.86 Million - $2.78 Million	72,000 Added 21.42%	408,100 $12.8 Million
Q1 2021 May 13, 2021	BUY	$39.27 - $91.68 $7.31 Million - $17.1 Million	186,100 Added 124.07%	336,100 $14.6 Million
Q3 2020 Nov 12, 2020	BUY	$26.2 - $30.13 $3.93 Million - $4.52 Million	150,000 New	150,000 $4.52 Million

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $48.7M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.